U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland. Corticotropin acts through the stimulation of cell surface the adrenocorticotropic hormone (ACTH) receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens). Corticotropin is indicated as monotherapy for the treatment of exacerbations of multiple sclerosis in adults and infantile spasms in infants and children under 2 years of age. Controlled clinical trials have shown Corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. The mechanism of action of Corticotropin in the treatment of infantile spasms is unknown.

Approval Year

1950
102
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
ACTHAR

Approved Use

H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.

Launch Date

-6.1534077E11
Primary
Approved
8429
ACTHAR

Approved Use

H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age; H.P. Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults; H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.

Launch Date

-6.1534077E11
PubMed

PubMed

TitleDatePubMed
Complications of corticotropin therapy in multiple sclerosis.
1966 Jul 18
Some observations on the hazards of corticosteroid therapy in patients with inflammatory bowel disease.
1967 Mar-Apr
Steroid myopathy complicating McArdle's disease.
1970 Feb
Reversible cerebral atrophy and corticotrophin.
1979 Jul 28
Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases.
1980 Feb
[Collateral transient behavioural changes during ACTH therapy in infantile generalized epilepsy (author's transl)].
1981 Mar-Jun
'Dystonia'-like postural asymmetry after microinjection of ACTH N-terminal fragments but not after ACTH1-39 in rat brainstem suggests role of neuropeptide mutation in genetic movement disorder.
1984 Feb 27
Suppressive action of ACTH on growth hormone secretion in patients with infantile spasms.
1985
Cerebral blood flow and brain shrinkage seen on CT during ACTH therapy.
1986
Administration of ACTH to suckling rats results in hyperkinetic behavior.
1986
[Long-term prognosis of infantile spasms after standard ACTH treatment in Japan].
1986 Sep
Infantile spasms in COFS syndrome.
1991 Jul-Aug
Activity of adenosine deaminase in red blood cells of patients suffering from multiple sclerosis treated with adrenocorticotropic hormone.
1995 Nov-Dec
Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy.
2003 Jul
Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells.
2004
Aryl hydrocarbon receptor activation impairs cortisol response to stress in rainbow trout by disrupting the rate-limiting steps in steroidogenesis.
2006 Apr
Repeated electroconvulsive stimuli increase brain-derived neurotrophic factor in ACTH-treated rats.
2006 Jan 4
Partial 17alpha-hydroxylase/17,20-lyase deficiency-clinical report of five Chinese 46,XX cases.
2008 Jul
Long-term weekly ACTH therapy for relapsed West syndrome.
2008 Jun
Chronic coadministration of carbamazepine together with imipramine produces antidepressant-like effects in an ACTH-induced animal model of treatment-resistant depression: involvement of 5-HT(2A) receptors?
2008 May
The role of ether-a-go-go-related gene K(+) channels in glucocorticoid inhibition of adrenocorticotropin release by rat pituitary cells.
2009 Jan 8

Sample Use Guides

In Vivo Use Guide
The usual dose of Corticotropin is 40-80 units given intramuscularly or subcutaneously every 24-72 hours.
Route of Administration: Other
Name Type Language
Corticotropin
GREEN BOOK   INN   ORANGE BOOK   USP   VANDF   WHO-DD  
INN  
Official Name English
CORTROPHIN
Brand Name English
CORTICOTROPIN [ORANGE BOOK]
Common Name English
ADRENOCORTICOTROPHIN
HPUS  
Common Name English
CORTICOTROPIN [USP-RS]
Common Name English
25-ASP-30-GLN-CORTICOTROPIN PORCINE
Common Name English
ACTH [MI]
Common Name English
CORTICOTROPIN [VANDF]
Common Name English
CORTICOTROPIN (ACTH)
Common Name English
ACTHAR
Brand Name English
ACTH
MI  
Brand Name English
CORTICOTROPHIN
Common Name English
CORTICOTROPIN [USP IMPURITY]
Common Name English
ADRENOCORTICOTROPIC HORMONE
Common Name English
corticotropin [INN]
Common Name English
Corticotropin [WHO-DD]
Common Name English
CORTICOTROPIN [GREEN BOOK]
Common Name English
ADRENOCORTICOTROPHIN [HPUS]
Common Name English
PURIFIED CORTROPHIN GEL
Brand Name English
.ALPHA.1-39-CORTICOTROPIN (SWINE), 25-L-ASPARTIC ACID-30-L-GLUTAMINE
Common Name English
Classification Tree Code System Code
CFR 21 CFR 862.1025
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 14674-6
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
WHO-VATC QH01AA01
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 15042-5
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 2141-0
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
FDA ORPHAN DRUG 168103
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
FDA ORPHAN DRUG 399113
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 6879-1
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 2140-2
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 16652-0
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
LOINC 66732-9
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000175941
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
WHO-ATC H01AA01
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
NDF-RT N0000006478
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
Code System Code Type Description
EVMPD
SUB01465MIG
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
CAS
12427-33-7
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
DRUG BANK
DB01285
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
FDA UNII
K0U68Q2TXA
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
CHEBI
3892
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
RXCUI
376
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1201610
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
LACTMED
Corticotropin
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
INN
1366
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
DRUG CENTRAL
4931
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
RS_ITEM_NUM
1149004
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
IUPHAR
3633
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
MERCK INDEX
m1395
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY Merck Index
DAILYMED
K0U68Q2TXA
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
NCI_THESAURUS
C212
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
PUBCHEM
16132265
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
MESH
D000324
Created by admin on Sat Dec 16 00:29:52 UTC 2023 , Edited by admin on Sat Dec 16 00:29:52 UTC 2023
PRIMARY
ACTIVE MOIETY
Corticotropin
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966